LSTA NASDAQ
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Basking Ridge, NJ 07920
US
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Farrow Jeffrey S | 0 | — | 2026-10-13 | |
| LOVE TED W | 0 | — | 2026-09-17 | |
| LOVE TED W | 2,270,316 | — | 2026-09-17 | |
| Lehrer-Graiwer Joshu | 0 | — | 2026-09-17 | |
| Lehrer-Graiwer Joshu | 0 | — | 2026-09-17 |